COVID-19 Vaccine Manufacture Information

**Pfizer and BioNTech**

Pharmacy manufacturers Pfizer and its partner, BioNTech, announced its first interim analysis, that its vaccine candidate is more than 95% effective. The study enrolled 43,538 participants and has not uncovered any serious safety concerns. Approval by the Federal Drug Administration (FDA) is expected soon after the required safety milestone is achieved. The clinical trial is ongoing, to collect further data and characterize the vaccine’s performance and effectiveness. Pfizer submitted on Nov. 20, 2020 an Emergency Use Authorization (EUA) application. [Get the press release.](#)

**Moderna**

Moderna announced that its first interim analysis, that its vaccine candidate is 94.5% effective. The study enrolled over 30,000 participants and has not identified any serious safety concerns. Moderna also intends to submit an EUA with the FDA in the coming weeks. The clinical trial will continue to final analysis of 151 confirmed cases, allowing the manufacturer to collect further data and continue to monitor and follow up with trial participants. By the end of 2020, Moderna expects to have approximately 20 million doses ready to ship in the U.S. The company remains on track to manufacture 500 million to 1 billion doses globally in 2021. [Get the press release.](#)